Humanized Mouse and Rat Model Market worth $338 million | Top Companies, Trends and Future Prospects Details for Business Development

Humanized Mouse and Rat Model Market worth $338 million | Top Companies, Trends and Future Prospects Details for Business Development
Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market
Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027 according to a new report by MarketsandMarkets™

The report “Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Oncology, Toxicology, Immunology & Infectious diseases, Hematopoiesis), End Users, and Region – Global Forecast to 2027″, is projected to reach USD 338 million by 2027 from USD 237 million in 2022, at a CAGR of 7.4% during the forecast period of 2022 to 2027.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

 

Factors such as advances in genomics, proteomics, and metabolomics; completion of the human genome map; the development of targeted diagnostics and therapeutics; and the growing emphasis on health, wellness, and preventive measures are driving the demand for personalized medicine and, subsequently the demand for relevant humanized mouse and rat research models. Also, grants from government and private organizations for cancer research have also supported the development of humanized models in oncology. For instance, in 2020, the US NIH funded a large-scale project to find treatments for rare genetic diseases with a five-year grant of USD 10,625,000 to The Jackson Laboratory Center for Precision Genetics. In the same year, The Jackson Laboratory received a grant from the NIH for its Mouse Mutant Resource and Research Centers (MMRRC) program, established in 2009. The new grant provides a total of USD 6,119,082 over five years to the MMRRC. With such grants and funding from the government and private sectors, the demand for humanized mouse models is expected to increase.

The genetic humanized mouse model segment accounted for the largest share of the humanized mouse model segment in the humanized mouse and rat model market in 2021.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. In 2021, genetic humanized mouse segment accounted for the largest share of humanized mouse model market. Advances in genetic engineering technologies, such as gene targeting and gene editing, have led to the development of genetically engineered humanized mouse models that serve as an important tool for a variety of research applications. In addition to the widespread use of these mice in diverse research areas, the emerging CRISPR technology, increasing focus on personalized medicine with the continuous introduction of new models, and various licensing agreements are expected to drive market growth.

The immunology and infectious diseases segment accounted for the second largest share of the application segment in the humanized mouse and rat model market in 2021.

Based on application, the humanized mouse and rat model market is segmented into oncology, immunology and infectious diseases, neuroscience, Hematopoiesis, toxicology, and other applications. Immunology and Infectious diseases segment accounted for the second largest share of the humanized mouse and rat model market in 2021. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. The use of mouse models allows suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes. They also assist in identifying the function of newly identified surface receptors in host defense as well as the developmental consequences of a disturbed signaling pathway or removing a transcription factor. Such mouse models are developed on a large scale in laboratories or institutes and are used for application in Immunology and Infectious diseases segment. Thus, making it the second largest segment in the market.

The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market in 2021.

Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.  The Asia Pacific market is estimated to register the highest growth during the forecast period. Global pharmaceutical firms are increasingly moving to APAC to tap into its thriving market and lower their production costs by shifting manufacturing and laboratory testing to the region. The rapidly increasing demand for the outsourcing of quality control safety testing (including efficacy testing) in countries such as China, India, Japan, and Singapore is expected to drive market growth in the Asia Pacific during the forecast period.

Key players in the humanized mouse and rat model Market include Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), and Envigo (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=131763955

Humanized Mouse and Rat Model Market Dynamics:

Drivers:

  1. Increasing research activities using humanized models
  2. Rising demand for personalized medicine
  3. Continuous support and initiatives from government and private sectors for cancer research
  4. Growing R&D activities in pharmaceutical and biotechnology sectors

Restraints:

  1. High cost of custom humanized models
  2. Laws and regulations for ethical use of animal models in research

Opportunities:

  1. Rising demand for humanized PDX models
  2. Emergence of CRISPR as a powerful tool in biomedical research
  3. Rising demand for humanized rat models

Challenges:

  1.  Alternatives for animal testing
  2. Limitations of humanized mouse models

Recent Developments:

  • In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
  • In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan’s Research Models & Services (RMS) business as a wholly-owned subsidiary.
  • In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.
  • In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River’s broad capabilities across the major CDMO platforms for cell and gene therapies.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131763955

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/humanized-mouse-model-market-131763955.html